The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer
Open accessAbstract
Myeloid-derived suppressor cells (MDSC) are one of the major factors limiting the efficacy of immune therapy. In a clinical trial of patients with extensive stage small cell lung cancer (SCLC), we tested the possibility that targeting MDSC can improve the induction of immune responses by a cancer vaccine. Forty-one patients with extensive stage SCLC were randomized into three arms: arm A—control, arm B—vaccination with dendritic cells transduced with wild-type p53, and arm C—vaccination in combination with MDSC targeted therapy with all-trans-retinoic acid (ATRA). Interim results of the ongoing clinical trial are presented. Pre-treatment levels of MDSC populations in patients from all three arms were similar. Vaccine alone did not affect the proportion of MDSC, whereas in patients treated with ATRA, the MDSC decreased more than twofold (p = 0.02). Before the start of treatment, no patients had detectable p53-specific responses in IFN-γ ELISPOT. Sequential measurements did not show positive p53 responses in any of the 14 patients from arm A. After immunization, only 3 out of 15 patients (20 %) from arm B developed a p53-specific response (p = 0.22). In contrast, in arm C, 5 out of 12 patients (41.7 %) had detectable p53 responses (p = 0.012). The proportion of granzyme B-positive CD8+ T cells was increased only in patients from arm C but not in arm B. Depletion of MDSC substantially improved the immune response to vaccination, suggesting that this approach can be used to enhance the effect of immune interventions in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Self-citationMyeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Self-citationAdoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Self-citationDiaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., & Rivoltini, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5829 · Cited by 647
Myeloid-derived suppressor cell heterogeneity and subset definition
Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., & Bronte, V. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.021 · Cited by 630
Mirza, N., Fishman, M., Fricke, I., Dunn, M., Neuger, A. M., Frost, T. J., Lush, R. M., Antonia, S., & Gabrilovich, D. I. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1690 · Cited by 564
Self-citationMechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells
Gabrilovich, D. I., Velders, M. P., Sotomayor, E. M., & Kast, W. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5398 · Cited by 538
Self-citationKusmartsev, S. A., Cheng, F., Yu, B., Nefedova, Y., Sotomayor, E. M., Lush, R. M., & Gabrilovich, D. I. (2003) · PubMed · Cited by 460
Self-citationAntonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444
Self-citationMechanism of All- Trans Retinoic Acid Effect on Tumor-Associated Myeloid-Derived Suppressor Cells
Nefedova, Y., Fishman, M., Sherman, S., Wang, X., Beg, A. A., & Gabrilovich, D. I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2593 · Cited by 423
Self-citationRetinoids regulate stem cell differentiation
Gudas, L. J., & Wagner, J. A. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22417 · Cited by 395
Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G. V., & Kiessling, R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3767 · Cited by 382
Solito, S., Falisi, E., Diaz-Montero, C. M., Doni, A., Pinton, L., Rosato, A., Francescato, S., Basso, G., Zanovello, P., Onicescu, G., et al. (2011) · Blood · doi:10.1182/blood-2010-12-325753 · Cited by 337
Nagaraj, S., Youn, J.-I., Weber, H., Iclozan, C., Lu, L., Cotter, M. J., Meyer, C., Becerra, C. R., Fishman, M., Antonia, S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3272 · Cited by 286
Self-citationReversal of Myeloid Cell–Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma
Kusmartsev, S., Su, Z., Heiser, A., Dannull, J., Eruslanov, E., Kübler, H., Yancey, D., Dahm, P., & Vieweg, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0165 · Cited by 284
Myeloid-Derived Suppressor Cells in Human Cancer
Nagaraj, S., & Gabrilovich, D. I. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb3358 · Cited by 223
Self-citationCirculating and tumor‐infiltrating myeloid cell subsets in patients with bladder cancer
Eruslanov, E., Neuberger, M., Daurkin, I., Perrin, G. Q., Algood, C., Dahm, P., Rosser, C., Vieweg, J., Gilbert, S. M., & Kusmartsev, S. (2012) · International Journal of Cancer · doi:10.1002/ijc.26123 · Cited by 205
Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples
Kotsakis, A., Harasymczuk, M., Schilling, B., Georgoulias, V., Argiris, A., & Whiteside, T. L. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.04.004 · Cited by 199
Immunotherapy earns its spot in the ranks of cancer therapy
Pardoll, D. M., & Drake, C. G. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112275 · Cited by 145
Golovina, T. N., Mikheeva, T., Brusko, T. M., Blazar, B. R., Bluestone, J. A., & Riley, J. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015868 · Cited by 133
Arrieta, O. G., la Rosa, C. H. G.-D., Aréchaga-Ocampo, E., Villanueva-Rodríguez, G., Cerón-Lizárraga, T., Martínez-Barrera, L. M., Vázquez-Manríquez, M. E., Ríos-Trejo, M. Á., Álvarez-Avitia, M. Á., Hernández‐Pedro, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6452 · Cited by 128
Van, Y.-H., Lee, W.-H., Ortiz, S., Lee, M.-H., Qin, H., & Liu, C. (2008) · Diabetes · doi:10.2337/db08-1154 · Cited by 124
Goedegebuure, P. S., Mitchem, J. B., Porembka, M. R., Tan, M. C. B., Belt, B. A., Wang‐Gillam, A., Gillanders, W. E., Hawkins, W. G., & Linehan, D. C. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911796191024 · Cited by 118
Montero, A. J., Diaz-Montero, C. M., Deutsch, Y. E., Hurley, J. E., Koniaris, L. G., Rumboldt, T., Yasir, S., Jorda, M., Garret-Mayer, E., Avisar, E., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1889-0 · Cited by 117
Retinoic Acid Attenuates Rheumatoid Inflammation in Mice
Kwok, S., Park, M.-K., Cho, M., Oh, H., Park, E., Lee, D., Lee, J. J., Kim, H., & Park, S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102706 · Cited by 101
Trellakis, S., Bruderek, K., Hütte, J., Elian, M., Hoffmann, T. K., Lang, S., & Brandau, S. (2012) · Innate Immunity · doi:10.1177/1753425912463618 · Cited by 96
Lee, J., Seo, J., Kim, Y., Kim, Y., Ko, H., & Kang, C. (2011) · International Journal of Cancer · doi:10.1002/ijc.26411 · Cited by 89
Nikitina, E. Y., Clark, J. I., van Beynen, J., Chada, S., Virmani, A. K., Carbone, D. P., & Gabrilovich, D. I. (2001) · PubMed · Cited by 82
Self-citationMechanism of synergistic effect of chemotherapy and immunotherapy of cancer
Ramakrishnan, R., & Gabrilovich, D. I. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0930-1 · Cited by 81
Self-citationMohty, M., Morbelli, S. D., Isnardon, D., Sainty, D., Arnoulet, C., Gaugler, B., & Olive, D. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04489.x · Cited by 69
Yuan, X.-K., Zhao, X.-K., Xia, Y.-C., Zhu, X., & Xiao, P. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900424 · Cited by 68
Randomized Phase II Trials: What Does Randomization Gain?
Wieand, H. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.956 · Cited by 59
Dark, G. G., Calvert, H., Grimshaw, R. N., Poole, C. J., Swenerton, K., Kaye, S. B., Coleman, R. E., Jayson, G. C., Le, T. V., Ellard, S. L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.028 · Cited by 58
Gervais, A., Lévêque, J., Bouet-Toussaint, F., Burtin, F., Lesimple, T., Sulpice, L., Patard, J., Genetet, N., & Quémener, V. (2005) · Breast Cancer Research · doi:10.1186/bcr1001 · Cited by 53
Song, X., Guo, W., Cui, J., Qian, X., Yi, L., Chang, M., Cai, Q., & Zhao, Q. (2010) · International Journal of Cancer · doi:10.1002/ijc.25451 · Cited by 19
Weiß, T., Vitacolonna, M., & Zöller, M. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31819b7b9e · Cited by 13
Cited by
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00490-y · Cited by 1,940
Self-citationMyeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Self-citationTumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Metadata
- Authors
- Iclozan, C., Antonia, S., Chiappori, A., Chen, D.-T., & Gabrilovich, D.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2013-04-16
- Volume
- 62
- Issue
- 5
- Pages
- 909-918
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2062873927
- Cited by
- 317
- References
- 46
- FWCI
- 15.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.